Impact of Delayed Erythropoietin Use in Critically Ill Patients
Author Information
Author(s): Duby Jeremiah J, Erstad Brian L, Abarca Jacob, Camamo James M, Huckleberry Yvonne, Bramblett Stuart N
Primary Institution: Kaiser Permanente
Hypothesis
What is the impact of delayed initiation of recombinant human erythropoietin (rHuEPO) for anemia of critical illness?
Conclusion
Delayed initiation of rHuEPO for anemia of critical illness resulted in comparable hemoglobin and transfusion benefits.
Supporting Evidence
- Eighty percent of patients were transfused with an average total of 5.42 units received.
- RBC exposure inversely correlated with a lower mean hemoglobin response to rHuEPO.
- The average change in hemoglobin from baseline to 28 days after starting rHuEPO was similar to that found in the RCT.
Takeaway
This study looked at how starting a treatment called erythropoietin later affects patients in the ICU who have low blood levels. It found that starting it later still helps with their blood levels and need for blood transfusions.
Methodology
Retrospective medical record review of patients treated with rHuEPO for anemia of critical illness.
Potential Biases
Efforts were made to reduce potential bias and inaccuracy, but retrospective design may introduce bias.
Limitations
The study was retrospective and lacked a control group.
Participant Demographics
Average age was 56.5 years; patients were admitted to medical or surgical ICUs.
Statistical Information
P-Value
p < 0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website